Dobutamine reverses the cardio-suppressive effects of terlipressin without improving renal function in cirrhosis and ascites: a randomised controlled trial.

CONCLUSION: Dobutamine reversed the cardio-suppressive effect of terlipressin in cirrhosis, ascites and impaired renal function. However, dobutamine reduced peripheral vascular resistance, activated RAAS and did not improve GFR compared to terlipressin as a monotherapy. Therefore, dobutamine cannot be recommended in cirrhosis and ascites. PMID: 31841026 [PubMed - as supplied by publisher]
Source: American Journal of Physiology. Gastrointestinal and Liver Physiology - Category: Physiology Authors: Tags: Am J Physiol Gastrointest Liver Physiol Source Type: research